29th week of 2010 patent applcation highlights part 45 |
Patent application number | Title | Published |
20100184763 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF - This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one quinolone based compound. This invention further involves assays for the detection of a hydroxyproline residue in a HW molecule. | 2010-07-22 |
20100184764 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia. | 2010-07-22 |
20100184765 | Protein Kinase Inhibitors and Methods for Using Thereof - The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, Blk, Bmx, BTK, C-Kit, CSK, C-Src, EphB1, EphB2, EphB4, FLT1, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRα, PDGFRβ, PKCα, SAPK2α, Src, SIK, Syk, Tie2 and TrkB kinases. | 2010-07-22 |
20100184766 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2010-07-22 |
20100184767 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF - The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders. | 2010-07-22 |
20100184768 | Isoprenyl Compounds and Methods Thereof - Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses. | 2010-07-22 |
20100184769 | PDE INHIBITORS FOR THE TREATMENT OF HEARING IMPAIRMENT - The invention provides pharmacological compositions comprising PDE-5 inhibitors for the treatment of hearing impairment i.e. hearing loss and tinnitus. The invention also provides methods of screening for such PDE-5 inhibitors for use in the preparation of medicaments for the treatment of hearing impairment i.e. hearing loss and tinnitus. | 2010-07-22 |
20100184770 | COMPOUNDS - The present invention relates to a compound of formula (I) | 2010-07-22 |
20100184771 | Bicyclic Heterocyclic Compound - A compound represented by the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof: | 2010-07-22 |
20100184772 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS - The present invention relates to substituted pyrazoline compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. | 2010-07-22 |
20100184773 | Germline Polymorphisms in the Angiogenic Pathway Predict Tumor Recurrence in Cancer Therapy - The invention provides compositions and methods for determining the likelihood of successful treatment with pyrimidine based antimetabolites and platinum-based alkylating agents. The methods comprise determining the identity of one or more genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response and treatment options. Patients identified as responsive are then treated with the appropriate therapy. | 2010-07-22 |
20100184774 | METHODS OF TREATMENT - This invention relates to a method of treating a disease state selected from: Alzheimer's disease, Down's syndrome, mental retardation, memory defects, memory loss, pancreatic cancer, bone resorption disease, osteoporosis, sickle cell anemia, chronic kidney disease, diabetes, depression, and subsets of depression including: alcoholism, anxiety, obsessive compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia and substance abuse, in a mammal in need thereof, including a human, which comprises administering to such mammal a therapeutically effective amount of a selected substituted thiazol compound. The invention also relates to a method of enhancing cognition in a mammal in need thereof which comprises administering to such mammal a therapeutically effective amount of a selected substituted thiazol compound. | 2010-07-22 |
20100184775 | ORGANIC COMPOUNDS - The present invention relates to compounds of formula (I) wherein n represents 0, 1, 2, 3, 4 or 5, R represents independent from each other hydroxyl, cyano, nitro, halogen, alkyl, alkoxy alkylcarbonyl, alkoxycarbonyl, alkylamine, dialkylamine, alkylcarbonylamine, alkylcarbamate Y represents one of the following groups: (Ia) in free base or acid addition salt form, to processes for their production, to pharmaceutical compositions comprising them and their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and neurodegenerative disorders. | 2010-07-22 |
20100184776 | PIPERIDINE/PIPERAZINE DERIVATIVES - The invention relates to a DGAT inhibitor of formula (I) including any stereochemically isomeric form thereof, wherein A represents CH or N; X represents O or NR | 2010-07-22 |
20100184777 | Substituted Pyrazinone Amides - The present invention provides compounds of Formula (I) | 2010-07-22 |
20100184778 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF - The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (Q) or (I), which penetrate the blood-brain barrier, inhibit the formation and accumulation of beta-amyloid, and are useful in the treatment of neurodegenerative diseases, particularly Alzheimer's disease. Further, the compounds of the present invention inhibit certain kinases, thereby being useful for the treatment of cancers of the central nervous system. | 2010-07-22 |
20100184779 | METHOD FOR OPTIMIZING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS - The present invention relates to a method for evaluating patients to help optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. More specifically, the method comprises the steps of (a) determining the OCT-1 Activity in pre-therapy blood of a warm-blooded animal suffering from CML, and (b) administering a daily dose between about 500 and 1200 mg of Imatinib mesylate to the warm-blooded animal suffering from CML showing an OCT-1 Activity corresponding to Imatinib intracellular concentration to below about 6.0 to 10.0 ng/200,000 cells, especially about 8.0 to 8.5 ng/200,000 cells. | 2010-07-22 |
20100184780 | INHIBITORS OF PROTEIN KINASES - The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I). | 2010-07-22 |
20100184781 | FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF - The present invention relates to novel oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof, and processes for preparing the same, and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof can be usefully employed as an anticoagulant for treating thromboembolism and tumors via inhibition of coagulation factor Xa. | 2010-07-22 |
20100184782 | FUSED BICYCLIC PYRIMIDINES - Compounds of formula (I) | 2010-07-22 |
20100184783 | COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY ATHEROSCLEROSIS COMPRISING A MAST CELL INHIBITOR AND A PPAR GAMMA AGONIST - There is provided combination products comprising (a) a mast cell inhibitor, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a PPAR | 2010-07-22 |
20100184784 | PHARMACEUTICAL COMPOSITIONS COMPRISING A MULTIFUNCTIONAL PHOSPHODIESTERASE INHIBITOR AND AN ADENOSINE UPTAKE INHIBITOR - The present invention relates to pharmaceutical compositions comprising at least one multifunctional phosphodiesterase inhibitor (MPDEI) and at least one adenosine uptake inhibitor. The present invention also relates to compositions comprising cilostazol and dipyridamole and their use. | 2010-07-22 |
20100184785 | PHARMACEUTICAL FORMULATION FOR THE PRODUCTION OF CHEWABLE TABLETS AND LOZENGES - The present invention relates to pharmaceutical formulations for the production of chewable and suckable tablets, comprising agglomerates based on sugar or sugar alcohols and disintegrant and water-insoluble polymers in combination with a viscosity-increasing/gel-forming polymer, and the corresponding chewable and suckable tablets. | 2010-07-22 |
20100184786 | Polar Quinazolines - Disclosed are polar quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): | 2010-07-22 |
20100184787 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors - The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders. | 2010-07-22 |
20100184788 | HETEROCYCLIC DERIVATIVES - The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, and heart failure development. | 2010-07-22 |
20100184789 | INHIBITORS OF PROTEIN KINASES - The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. | 2010-07-22 |
20100184790 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF - The invention relates to pyrrolo[2,3-b]pyridine compounds and azaindole compounds used for the synthesis thereof. The invention also relates to methods for the production thereof and the uses thereof. Said novel pyrrolo[2,3-b]pyridine compounds according to the invention have great antiproliferative, apoptotic, and neuroprotective activities. The invention particularly applies to the pharmaceutical field. | 2010-07-22 |
20100184791 | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. | 2010-07-22 |
20100184792 | Co-Crystals of Pyrimethanil and Dithianon - The present invention relates to co-crystals of pyrimethanil and dithianon, which, in a X-ray powder diffractogram at 25° C. show at least three of the following reflexes:
| 2010-07-22 |
20100184793 | COMPOSITIONS INCORPORATING SESAMIN-CLASS COMPOUNDS AND VITAMIN B1 CLASS COMPOUNDS - A composition incorporating at least one sesamin-class compound is enhanced in the anti-fatigue action of sesamin class compounds by additionally incorporating at least one vitamin B | 2010-07-22 |
20100184794 | FUSED HETEROCYCLIC COMPOUND - The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like. | 2010-07-22 |
20100184795 | ASPARTATE OF 1-CYCLOPROPYL-6-FLUORO-7-(8-METHOXYIMINO-2,6-DIAZA-SPIRO[3.4]OCT-6-YL)-4-- OXO-1,4-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHOD FOR PREPARING THE SAME, AND ANTIMICROBIAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are aspartic acid salts of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, methods for preparing the same, and antimicrobial pharmaceutical compositions comprising the same. | 2010-07-22 |
20100184796 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF - The present invention relates to agonists of the human bitter-taste receptors hTAS2R46, hTAS2R47 and hTAS2R50 and their role in bitter taste transduction. The invention also relates to methods for identifying molecules that modulate, e.g. suppress, or enhance hTAS2R46, hTAS2R47 and hTAS2R50 bitter taste transduction or bitter taste response. | 2010-07-22 |
20100184798 | Methods to Predict Cholesterol Elevations during Immunosuppressant Therapy - This invention provides methods to predict the degree of elevation of serum cholesterol levels in patients treated with immunosuppressive medication. This invention also provides treatment strategies based on these predictions and kits to carry out these methods. | 2010-07-22 |
20100184799 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS - Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 2010-07-22 |
20100184800 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2010-07-22 |
20100184801 | FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS - The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors. | 2010-07-22 |
20100184802 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof - Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others. | 2010-07-22 |
20100184803 | Treatment of Lysosomal Storage Diseases - Methods and compositions useful in the treatment or prevention of lysosomal storage diseases, such as Pompe's disease, Fabry's disease, Gaucher's disease, and Niemann-Pick disease, are provided. The treatment includes administering to a subject a farnesyl transferase inhibitor compound. The treatment may also include enzyme replacement therapy or gene therapy. | 2010-07-22 |
20100184804 | METHODS FOR THE PREVENTION OR TREATMENT OF BACTERIAL AND FUNGAL INFECTIONS - The present invention features improved methods for treating, stabilizing, or preventing a bacterial or a fungal infection in a plant or an animal, such as a mammal. In particular, these methods involve the use of a compound, that is controlled by MvfR, and that affects the expression of an MvfR protein or that promotes its modification or inactivation, or a compound produced by | 2010-07-22 |
20100184805 | RENIN INHIBITORS - Disclosed are aspartic protease inhibitors represented by the following structural formula: and pharmaceutically acceptable salts thereof. These compounds are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. The present invention is also directed to pharmaceutical compositions comprising a compound described herein or enantiomers, diastereomers, or salts thereof and a pharmaceutically acceptable carrier or excipient. | 2010-07-22 |
20100184806 | MODULATION OF NEUROGENESIS BY PPAR AGENTS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a nervous system disease or disorder. | 2010-07-22 |
20100184807 | Methods to inhibit tumor cell growth by using proton pump inhibitors - Methods of treating one or more growth deregulated cells are disclosed: An effective amount of a pharmaceutical composition including a proton pump inhibitor is administered thereby treating a growth deregulated cell outside of the gastric lumen of a subject. | 2010-07-22 |
20100184808 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS - The invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of the formula (I) wherein R | 2010-07-22 |
20100184809 | Heterocyclic FXR Binding Compounds - The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds. | 2010-07-22 |
20100184810 | METHODS AND COMPOSITIONS RELATED TO RIBOSWITCHES THAT CONTROL ALTERNATIVE SPLICING - Disclosed are methods and compositions related to riboswitches that control alternative splicing. | 2010-07-22 |
20100184811 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS - The invention relates to the use of a compound(s) selected from isoniazid and isoniazid analogs of formula Ia, wherein R is —C(O)NHNH | 2010-07-22 |
20100184812 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER - Mutual prodrugs comprising retinoids and histone deacetylase inhibitors, methods for production of the mutual prodrugs, and methods of treatment comprising administration of the mutual prodrugs. The retinoids include all-trans retinoic acid, 13-cis retinoic acid, and retinoic acid analogs that have a substitution at C-4. Further, the mutual prodrugs of the present invention can be used as therapeutic agents for the treatment of cancer and dermatological diseases and conditions. Pharmaceutical compositions comprising the mutual prodrugs. | 2010-07-22 |
20100184813 | CHEMICAL COMPOUNDS 553 - DGAT-1 inhibitor compounds of formula (I) and pharmaceutically-acceptable salts thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity | 2010-07-22 |
20100184814 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof - The present invention relates to compounds represented by the formula (I) as prodrugs of the formula (II) (Losartan) and their salts, solvates, hydrates, polymorphs, optical isomers, enantiomers, and pharmaceutical compositions comprising these compounds and methods of preparing them and administering them for the treatment of circulatory diseases such as hypertension, congestive heart failure, angina, and the like. | 2010-07-22 |
20100184815 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA - Disclosed are compounds of the formula: | 2010-07-22 |
20100184816 | Method for Reducing the Phytotoxicity of Azoles on Dicotyledonous Plants by Adding Additives - The present invention relates to a method for reducing the phytotoxicity of azoles on dicotyledonous plants by addition of additives. Furthermore, the application relates to novel compositions comprising certain triazole fungicides in combination with additives, in particular alkali metal sulphosuccinates, and their use for controlling unwanted phytopathogenic fungi. | 2010-07-22 |
20100184817 | METHODS OF TREATING NEUROPATHY - Methods and compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and methods for administering the compositions to treat various neuropathies. | 2010-07-22 |
20100184818 | PHOTOSENSITIZERS FOR TARGETED PHOTODYNAMIC THERAPY - The present invention provides photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof. | 2010-07-22 |
20100184819 | METHOD FOR REDUCING INTRACRANIAL PRESSURE - The present invention relates generally to methods for reducing intracranial pressure in a subject. More particularly, the methods of the present invention include administering to the subject an effective amount of a substance P receptor antagonist. | 2010-07-22 |
20100184820 | COMBINATIONS COMPRISING STAUROSPORINES - The present invention relates to a method of treating myelodysplastic syndromes, lymphomas and leukemias, and also solid tumors with a pharmaceutical combination of a FLT-3 kinase inhibitor and an antisense oligonucleotide or a mcl-1-specific RNAi construct. It also relates to the use of a pharmaceutical combination of a histone deacetylase inhibitor and a FLT-3 kinase inhibitor for the treatment of the diseases or malignancies mentioned above and the use of such a pharmaceutical composition for the manufacture of a medicament for the treatment of these diseases or malignancies. | 2010-07-22 |
20100184821 | Compositions and Methods for Modulating Angiogenesis - The invention generally features compositions and methods that are useful for modulating angiogenesis. | 2010-07-22 |
20100184822 | Method of modulating the activity of a nucleic acid molecule - The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same. | 2010-07-22 |
20100184823 | dsRNA For Treating Viral Infection - The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propagation of positive stranded RNA viruses in and between cells. | 2010-07-22 |
20100184824 | RNA Interference Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid (siNA) - This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of interleukin and/or interleukin receptor genes. | 2010-07-22 |
20100184825 | RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering Nucleic Acid (siNA) - This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of PTP-1B genes. Such small nucleic acid molecules are useful, for example, for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes (eg. type II and type I diabetes) in a subject or organism, and for any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue, alone or in combination with other treatments or therapies. | 2010-07-22 |
20100184826 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 2010-07-22 |
20100184827 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 2010-07-22 |
20100184828 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 2010-07-22 |
20100184829 | RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell. | 2010-07-22 |
20100184830 | Compositions and Methods for the Diagnosis and Therapy of BCL2-Associated Cancers - The invention provides methods and compositions for the treatment of cancers associated with overexpression of a BCL2 gene and/or gene product in a subject, and methods and compositions for the improvement of anti-cancer therapy, such as chemotherapy and radiation therapy. The invention also encompasses methods for determining the efficacy of a cancer therapy in a subject and methods for inducing apoptosis of a cell. | 2010-07-22 |
20100184831 | Materials and Complexes for the Delivery of Biologically-Active Materials to Cells - The invention provides a peptide derivative of formula A-B-C wherein A is a polycationic nucleic acid-binding component; B is a spacer element peptide that is susceptible to cleavage within a cell; and C is a cell surface receptor binding component. The invention also provides a lipid derivative of general formula (I): (PEG) | 2010-07-22 |
20100184832 | Construction of Recombinant Virus Vaccines by Direct Transposon-Mediated Insertion of Foreign Immunologic Determinants into Vector Virus Proteins - The invention provides viral vectors, such as chimeric flavivirus vectors, including foreign peptides inserted into the target proteins of the vectors, methods of making and using these vectors, and compositions including the vectors. | 2010-07-22 |
20100184833 | METHODS AND MEANS FOR TREATING DNA REPEAT INSTABILITY ASSOCIATED GENETIC DISORDERS - The current invention provides for methods and medicaments that apply oligonucleotide molecules complementary only to a repetitive sequence in a human gene transcript, for the manufacture of a medicament for the diagnosis, treatment or prevention of a cis-element repeat instability associated genetic disorders in humans. The invention hence provides a method of treatment for cis-element repeat instability associated genetic disorders. The invention also pertains to modified oligonucleotides which can be applied in method of the invention to prevent the accumulation and/or translation of repeat expanded transcripts in cells. | 2010-07-22 |
20100184834 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME - The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides. | 2010-07-22 |
20100184835 | Devices, Systems and Methods for Improving Memory and/or Cognitive Function Through Brain Delivery of Sirna - The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject. | 2010-07-22 |
20100184836 | VACCINE - This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them. The polypeptide may also comprise Pol or RT or an immunogenic fragment thereof. | 2010-07-22 |
20100184837 | Small-molecule nucleotide aptamer for hepatitis C virus, preparation method and use thereof - A DNA aptamer specific for HCV having a nucleotide sequence as shown in SEQIDNO.1-29, and a method of preparing the same including the steps of: (1) constructing a single-stranded DNA library; (2) constructing a double-stranded DNA library; (3) screening by SELEX; (4) amplifying by PCR; (5) cloning and sequencing; and (6) testing the effect from cellular level in vitro. The DNA aptamer can be used directly as medication and diagnostic reagent for detection, prevention, and treatment of hepatitis C. A method for detection of HCV infection is also provided. | 2010-07-22 |
20100184838 | Compositions and methods for retinal transduction and photoreceptor specific transgene expression - Adenovirus (Ad) vectors are here provided for treatment of ocular tissues as are suitable methods to transduce photoreceptor (PR) cells, the tissue associated with degeneration. Expression from CMV or chicken beta actin (CBA) promoters in neural retina were compared, and CBA was found to be 173-fold more potent than CMV. Further, the RGD domain in Ad penton was found to play a key role in RPE tropism. Deletion of the RGD domain coupled with the CBA promoter permitted transgene expression in neural retina approximately 667-fold more efficiently than with prior Ad5 vectors. Use of Ad vectors in combination with a 4.7 kb rhodopsin promoter enabled transgene expression exclusively in photoreceptor cells in vivo. | 2010-07-22 |
20100184839 | ALLELIC POLYMORPHISM ASSOCIATED WITH DIABETES - The invention relates to the identification of allelic polymorphism in a diabetes associated gene, particularly in a gene encoding phosphofructokinase (PFK) and use thereof for diagnosing diabetes predisposition and state and for predicting the response to a therapeutic agent. | 2010-07-22 |
20100184840 | PRIMARY MICRO RNA EXPRESSION CASSETTE - This invention relates to inhibition of hepatitis gene expression. More specifically, the invention relates to a method of using RNA sequences to inhibit Hepatitis B and C Virus replication. Expression cassettes that include DNA sequences derived from endogenous micro RNAs (miRs) are used in the method and are transcribed by Pol II promoters, and then processed to generate sequences that are specific to target hepatitis virus sequences (RNAi effecter sequences). The RNAi effecter sequences can target the selected hepatitis virus sequences resulting in gene silencing or transcriptional inhibition of the hepatitis virus gene. The expression cassettes may be delivered in vitro or in vivo to host cells. A pharmaceutical composition containing the expression cassettes is also claimed. | 2010-07-22 |
20100184841 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION - The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a pattern of deoxyribonucleotides (in most embodiments, the pattern comprises at least one deoxyribonucleotide-deoxyribonucleotide base pair) designed to direct the site of Dicer enzyme cleavage within the dsNA molecule. Deoxyribonucleotides of the dsNA molecules of the invention are located within a region of the dsNA that can be excised via Dicer cleavage to generate an active siRNA agent that no longer contains the deoxyribonucleotide pattern (e.g., deoxyribonucleotide-deoxyribonucleotide base pairs). Such DNA-extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be more effective RNA inhibitory agents than corresponding double stranded RNA-extended DsiRNAs. DsiRNA agents were also found to tolerate guide strand mismatches. | 2010-07-22 |
20100184842 | Ultraconserved Regions Encoding ncRNAs - Described herein are methods for differentiate human cancers comprising using one or more transcribed ultraconserved regions (T-UCR) expression profiles where the association between the genomic location of UCRs and the analyzed cancer-related genomic elements is highly statistically significant and comparable to that reported for miRNAs. | 2010-07-22 |
20100184843 | IDENTIFICATION OF A PIN SPECIFIC GENE AND PROTEIN (PIN-1) USEFUL AS A DIAGNOSTIC TREATMENT FOR PROSTATE CANCER - The invention relates to nucleic acids encoding a mammalian ABCA5 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, PIN. Further, the invention relates to diagnostic assays for identifying the DNA-binding protein ABCA5 (also known as PIN-1). The invention also relates to oligonucleotide sequence(s) or antibodies that specifically bind with ABCA5 or variants thereof. | 2010-07-22 |
20100184844 | Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates - The present invention is directed to oligonucleotide-modified nanoparticle conjugates and methods of inhibiting bacterial protein production. | 2010-07-22 |
20100184845 | Myeloid Colony Stimulating Factor and Uses Thereof - The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5- may be used to enhance the immune response to viral infection or other diseases associated with immune suppression. | 2010-07-22 |
20100184846 | Methods for the formulation and manufacture of artesunic acid for injection - A method for the manufacture of a sterile intravenous or intramuscular formulation of artesunic acid and the formulation are the subject of this invention. First the artesunic acid powder is sterilized with ethylene oxide and placed into a sterile container. The contained sterilized powder is then dissolved in sterile sodium phosphate buffered solution to produce an injectable intravenous or intramuscular formulation. The sodium phosphate dissolves and dilutes the artesunic acid powder without caking or frothing resulting in an improved drug product. The invention also relates to the formulation and a method of treating a patient with either uncomplicated or severe and complicated malaria. | 2010-07-22 |
20100184847 | COMPOSITIONS FOR SKIN PROTECTION AND IMPROVEMENT OF SKIN DISEASES CONTAINING THE DIBENZO-P-DIOXINE DERIVATIVES - The present invention relates to compositions for skin protection and improvement that contain dibenzo-p-dioxine derivatives as effective components. Since the compositions for skin protection and improvement that contain the dibenzo-p-dioxine derivative according to the present invention have excellent functions such as moisturizing and/or wrinkle prevention which are useful in prevention and improvement of various skin diseases, they can be extensively used as cosmetic ingredients or pharmaceutical agents for prevention and improvement of skin diseases. | 2010-07-22 |
20100184848 | TRANSDERMAL FORMULATIONS OF SYNTHETIC CANNABINOIDS AND NANO COLLOIDAL SILICA - The present invention relates to pharmaceutical compositions comprising cannabinoids or mimics thereof. In one aspect, the invention provides transdermal formulations comprising cannabinoids or mimics thereof. In another aspect, the invention provides topical formulations comprising cannabinoids or mimics thereof. In one embodiment the formulations and compositions of the invention comprise nano colloidal silica. The formulations of the invention can be used in the therapeutic treatment of many conditions, including wherein the cannabinoids or mimics thereof are known to reduce the excessive neuronal firing characteristic of neuropathic pain. Muscle spasticity is also benefited by these formulations. | 2010-07-22 |
20100184849 | UREA OLIGOMERS, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - A method for treating a cytotoxic disease by administrating compounds having a general formula X-(A)n-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an RaCO, RaOCO, RaNHCO or RaSO2 group, Ra being an alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl group, the groups being substituted or not, on condition that X is different from H when n is equal to 6; A denotes either a group having formula (I) or (II), wherein Ri is a hydrogen atom, an amino acid side chain, an alkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl group, said groups being substituted or not, i being an integer of between 1 and n; Y is an NRbRc, Rb and Rc group having the same meaning as given earlier for Ra. | 2010-07-22 |
20100184850 | PHENOLIC EXTRACTS OF ALMOND PEEL CONTAINING PROCYANIDINS, PROPELARGONIDINS, AND PRODELPHINIDINS, AND METHOD FOR PREPARATION THEREOF - The present disclosure concerns phenolic extracts containing procyanidins, propelargonidins and prodelfinidins obtained from peel of the almond [ | 2010-07-22 |
20100184851 | INHIBITION OF CELL PROLIFERATION - Compounds of formula (I) and (II) are provided as modulators of Rb:Raf-1 interactions which are potent, selective disruptors of Rb:Raf-1 binding. Therapeutic methods of using the compounds, for example for treating or ameliorating a cell proliferation disorder such as cancer, are provided. | 2010-07-22 |
20100184852 | ORGANIC COMPOUNDS FOR TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION - The present invention refers to compounds of the general formula (I) wherein R | 2010-07-22 |
20100184853 | TERPENES WITH ANTIFUNGAL ACTIVITY AGAINST MALASSEZIA YEASTS - The present invention relates to the use of some terpenes, for example chlovalicin, ovalicin or fumagillin, as antifungal against | 2010-07-22 |
20100184854 | PLATINUM (IV) COMPLEXES AND METHODS OF USE THEREOF - Provided are nitroplatinum(IV) complexes which may be useful treating various forms of proliferative diseases, such as cancer. In some instances the platinum(IV) complexes are relatively stable and may be suitable for oral administration. Also provided are methods of treatment, as well as kits and unit dosages. | 2010-07-22 |
20100184855 | Hard Surface Cleaner Compositions of Sulfonated Estolides and Other Derivatives of Fatty Acids and Uses Thereof - Sulfo-estolides and formulations of sulfo-estolides in and as hard surface cleaners, glass cleaners, toilet bowl cleaners, carpet cleaners, all purpose cleaners, floor cleaners, and others are described. Further details of cleaning performance, stability of diluted and concentrated forms and contemplated cleaning applications are provided. | 2010-07-22 |
20100184856 | Novel Compounds and Uses Thereof for Treating Inflammation and Modulating Immune Responses - The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity. | 2010-07-22 |
20100184857 | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATION AND THE TREATMENT OR PREVENTION OF GASTRIC TOXICITY - The invention provides hops ( | 2010-07-22 |
20100184858 | Hepatic fibrosis inhibitor - The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: | 2010-07-22 |
20100184859 | MEDICAMENT HAVING PROMOTING ACTION ON HEPATOCYTE PROLIFERATION - A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient. | 2010-07-22 |
20100184860 | Novel Carboxylic Acid and Antidepressant Composition Containing the Same as Active Ingredient - The present invention provides a novel compound and antidepressant composition that can be effectively used for improving depressed mood and depressed state, particularly for depressed mood and depressed state in menopausal women. The compound of the present invention is represented by the following formula (1): | 2010-07-22 |
20100184861 | METHOD AND APPARATUS FOR DRY GRANULATION - The invention provides, inter alia, a method for producing granules from a powder, characterized in that compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the other granules by entraining the fine particles and/or small granules in a gas stream. Also provided are apparatus for use in the process and tablets formed by compression of the resultant granules. | 2010-07-22 |
20100184862 | PROSTACYCLIN DERIVATIVES - This invention relates to novel prostacyclin derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors. | 2010-07-22 |
20100184863 | SYNTHETIC SPILANTHOL AND USE THEREOF - The present application provides a synthetic spilanthol flavor composition that includes (2E,6Z,8E)-N-(2-methylpropyl)-2,6,8-decatrienamide. The synthetic spilanthol composition can also contain, and at least one of (2E, 6E, 8E)-N-(2-methylpropyl)-2,6,8-decatrienamide and (2E, 6Z, 8Z)-N-(2-methylpropyl)-2,6,8-decatrienamide, the (N-(2-methylpropyl)-2,6,8-decatrienamide being present in amounts effective to impart a salivating or tingle effect while reducing the perception of off notes, as compared to the off-notes perceived upon consumption of natural spilanthol (e.g. spilanthol obtained from jambu oleoresin). Methods of increasing salivation and/or providing a tingling sensation upon consuming an orally consumable product that include adding to the product a synthetic spilanthol flavor composition are also provided. Synthetic spilanthol flavor compositions can be added to orally consumed products, such as, but not limited to, foods, beverages, pharmaceuticals, nutraceuticals, or therapeutic compositions, oral personal care products, gums (e.g. chewing gum or bubble gum), candy or lozenges. | 2010-07-22 |